5 YEARS OF DATA ON EVRYSDI DRUG WITH RISDIPLAM ACTIVE INGREDIENT ARE PRESENTED.

5-year data on the Evrysdi drug with the active ingredient Risdiplam was presented. It was observed that children with SMA who received Risdiplam treatment gained the ability to sit, stand or walk and maintained these skills.

After five years of treatment, 91% of the children were alive, 96% of them can swallow, 80% of them have a feeding tube. It has been observed that 59% of them can feed without support and 59% can sit without support for at least 30 seconds.

Evrysdi treatment More than 100 patients worldwide It is approved in the country and used by more than 15,000 patients. You can click.